UK and EU Clear tDCS Headband for PMDD Anxiety Symptoms

A consumer transcranial direct current stimulation (tDCS) headband gained approval on 5 November for managing anxiety symptoms of premenstrual dysphoric disorder (PMDD) in the United Kingdom and European Union. The device, made by London-based Samphire Neuroscience, was already cleared in the same regions to treat menstrual pain and premenstrual syndrome (PMS).

The expansion rests on an independent study of 42 participants led by Paul Faulkner, a psychology researcher at Queen Mary University of London. The results have been submitted for peer review but remain unpublished. "PMDD has very few treatment options, and even those that do exist all have significant side effects," Faulkner said. "This study was easy to recruit for simply because women with PMDD receive no support, and so are (understandably) desperate for help."

PMDD, sometimes described as a severe form of PMS, affects up to 10 percent of women. Normal hormonal fluctuations trigger it, but scientists believe it disrupts neurotransmitters including serotonin — the same imbalances linked to depression and anxiety. Around one in five women report strong menstrual symptoms that disrupt daily life.

How the stimulation protocol works

The headband carries four scalp electrodes, each contacting the skin through the hair with a saline-wetted sponge. Electrodes near the forehead stimulate the dorsolateral prefrontal cortex, a region associated with mood regulation. Electrodes placed farther back target a pain-regulation region deep inside the cerebral cortex via the motor cortex, according to Samphire CEO and co-founder Emilė Radytė.

In the trial, participants completed one 20-minute session per day for two weeks before their period — the luteal phase. Real-world users may run ten to thirty sessions per month, guided by a phone app and algorithm. The current has often been compared to a 9-volt battery. Unlike brain implants, tDCS requires no surgery; unlike transcranial magnetic stimulation, it requires no clinic visits. "It's the most scalable option out there," Radytė said.

What did the trial show?

The outcomes split by symptom. For depressive symptoms, the trial found no observable difference between treatment and a sham condition — possibly a strong placebo effect, according to Faulkner. After the first month, however, patients receiving treatment reported anxiety symptoms less frequently, and the company says they also had less difficulty regulating emotion.

The side-effect profile favors the device over pharmaceutical alternatives: minor electrode burns are the primary reported adverse effect of at-home tDCS. By comparison, antidepressant medications used for PMDD carry more disruptive side effects, Faulkner noted.

Cleared device or wellness gadget?

In Europe, the headband is sold as a regulated medical device under the name Nettle. Elsewhere, including the United States, it is sold as a wellness device called Lutea, "for conditions that wouldn't be recognized as requiring regulation," Radytė said. Both sell through the same website, with price and labeling varying by location.

"As a consumer, I don't think it's clear," said Anna Wexler, a medical ethicist at the University of Pennsylvania who studies tDCS. She also noted that research has not always accounted for diversity, such as the effect of hair texture on efficacy. Samphire sells an accessory strap designed to maintain scalp contact through thick or curly hair.

The U.S. Food and Drug Administration first authorized a tDCS device — Flow Neuroscience's headband for major depression — in late 2025, available by prescription. The Samphire PMDD indication remains a UK and EU approval, not an FDA clearance.

What comes next

Wexler described women's health as "an area of unmet need" within neuromodulation research. Samphire plans to arrange reimbursement through insurers and healthcare groups and to investigate endometriosis pain as a next application. Faulkner aims to optimize the protocol and identify which patients benefit most. Five percent of Samphire's users are men, according to Radytė. The company's near-term test will be whether unpublished trial data survive peer review and whether insurers agree to pay.